A phase I trial of SAGE-324 for essential tremor

Trial Profile

A phase I trial of SAGE-324 for essential tremor

Phase of Trial: Phase I

Latest Information Update: 11 Jan 2018

At a glance

  • Drugs SAGE-324 (Primary)
  • Indications Tremor
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Jan 2018 New trial record
    • 08 Jan 2018 According to a Sage Therapeutics media release, this trial is expected to begin in 1H 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top